Renaissance Technologies’s Biodexa Pharmaceuticals BDRX Stock Holding History

Renaissance Technologies’s Portfolio BDRX Stock Details BDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9	Closed	-$31K	–	3708
2023 Q4	$31K	Buy	+9	New	+$38.2K	﹤0.01%	3525
2023 Q2	–	Sell	-1	Closed	-$21K	–	3912
2023 Q1	$21K	Buy	+1	New	+$225K	﹤0.01%	3811
2022 Q4	–	Hold	0	–	–	–	3864
2022 Q3	–	Hold	0	–	–	–	3679
2022 Q2	–	Hold	0	–	–	–	3824
2022 Q1	–	Hold	0	–	–	–	3680
2021 Q4	–	Hold	0	–	–	–	3483
2021 Q3	–	Hold	0	–	–	–	2997
2021 Q2	–	Hold	0	–	–	–	3010
2021 Q1	–	Hold	0	–	–	–	2738
2020 Q4	–	Hold	0	–	–	–	2992
2020 Q3	–	Hold	0	–	–	–	3026
2020 Q2	–	Hold	0	–	–	–	3313
2020 Q1	–	Hold	0	–	–	–	3361
2019 Q4	–	Hold	0	–	–	–	3317
2019 Q2	–	Hold	0	–	-$150K	–	3541
2019 Q1	–	Hold	0	–	–	–	3248
2016 Q2	–	Hold	0	–	-$85K	–	3326
2016 Q1	–	Hold	0	–	–	–	3232
2015 Q4	–	Hold	0	–	–	–	2994

Other funds holding BDRX

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies's BDRX Position: Q1 2024 in Review

Renaissance Technologies sold out of Biodexa Pharmaceuticals (BDRX) in Q1 2024, closing a stake of 9 shares — an estimated $31K sold.

Renaissance Technologies first reported a position in BDRX in Q1 2023 and held it in 2 quarters. The position peaked at $31K in Q4 2023. 3 funds tracked by Wall St. Rank hold BDRX as of Q1 2024.

Renaissance Technologies reported no remaining Biodexa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Renaissance Technologies sold 9 Biodexa Pharmaceuticals shares in Q1 2024, an estimated $31K.
Renaissance Technologies first reported a position in Biodexa Pharmaceuticals in Q1 2023 and held it in 2 quarters.
Renaissance Technologies's Biodexa Pharmaceuticals position peaked at $31K in Q4 2023.
3 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q1 2024.

Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.